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ABSTRACT  
Objective: The present study was aimed to design different analogues of 2-aminobenzimidazole and find the binding ability by Insilico method.  
Methods: Various soft wares like Chemsketch, Molinspiration, PASS, and Discovery studio were used to design the proposed derivatives. Evaluation 
of binding activity against different receptors was detected and checked their physicochemical properties for binding.  
Results: In this study, we designed different analogs of 2-aminobenzimidazole into a ligand having a binding affinity with alpha-glucosidase, 
Dipeptidyl–peptidase 4(DPP4), Peroximase proliferator-activated receptor gamma (PPARγ), and Insulin-like growth factor 1(IGF-1) receptor. The 
designed ten derivatives showed a significant binding capacity to the concerned receptors. 
Conclusion: These results pointed that the designed proposed derivatives promising hypoglycaemic activity.  
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INTRODUCTION  
Diabetes is a metabolic disorder leads to the elevated glucose level 
in the blood due to the insufficient secretion of insulin by pancreas 
[1]. Diabetic patients were shown obesity, high concentration of 
triglycerides or low concentration of High-Density Lipid (HDL) 
cholesterol and, increased maturation rate. Diabetes is characterised 
by hyperglycemia, polyurea weight loss and blurred vision. 
Prolonged diabetes led to retinopathy, nephropathy and autonomic 
neuropathy [2]. The α-glucosidase receptor inhibitors [3], 
Dipeptidyl–peptidase 4(DPP4) inhibitors [4], Peroximase 
proliferator-activated receptor gamma (PPARγ) agonists, and 
Insulin-like growth factor-1 inhibitors (IGF-1) [5] played a major 
role in the antidiabetic activity. Drug design is the process for the 
development of biophore as a lead moiety which can be modified as 
a drug through various processes and produced the desired action in 
biological system [6]. Computer-aided drug design (CADD) is a modern 
technique in medicinal chemistry used to predict how to convert a lead 
moiety into a drug, how its combine with the receptor of known 3D 
structures [7-11]. Computer-aided drug design (CADD) disclosed the 
various methods to generate a drug moiety with less time-consuming 
processes. Application of Computer aided drug design (CADD) in 
medicinal chemistry led to predict how to convert a lead moiety into a 
drug, how its combine with the receptor of known 3D structures. 
Docking is a computational method to find out the binding affinity of a 
lead with the receptor and to form a stable complex. In silico method 
succor to modify the binding mode to attain a better fit between the 
ligand and receptor by changing their steric and electrostatic hindrances. 
The top pose of the molecule having optimized energy is selected for 
docking into the binding sites. 
The intention of ligand-protein docking is to anticipate the 
predominant binding mode(s) of a ligand with a protein of known 
three-dimensional structures.  
The Structurae Activity Study (SAR) study reveals that the amino 
group present at C2 position of Benzimidazole changes the biological 
activity of the parent nucleus. In this research, we have developed 
some new derivatives of 2-aminobenzimidazole and evaluate their 
hypoglycaemic activity by finding their binding capacity on different 
diabetic receptors like α-glucosidase, Peroximase proliferator-
activated receptor gamma (PPARγ), Dipeptidyl–peptidase 4(DPP4), 
and Insulin like growth factor-1 (IGF-1) by means of Discovery 
Studio [12]. α-glucosidase breakdown carbohydrates into glucose 
and other simple sugars that can be absorbed. Activation of 
Peroximase proliferator-activated receptor gamma (PPARγ) 
regulates the transcription of several insulin-responsive genes, 
resulting in increased insulin sensitivity in adipose tissue, liver and 
skeletal muscle. Dipeptidyl–peptidase 4(DPP4) inhibitors inhibit the 
enzyme Dipeptidyl–peptidase 4(DPP4), which is responsible for the 
inactivation of incretin hormone such as GLP-1which interfere 
glucagon release. The binding energy of the proposed ligands 
compared with that of markedly available standard drugs. 
MATERIALS AND METHODS  
In this research work, we have used different software for evaluating 
the proposed derivatives of 2-aminobenzimidazole. ACD Lab 
Chemsketch was used to draw the 3D structure of ligands. This 
software reveals the Lipinski rule of five [13]. Molinspiration 
software was used for drug-likeness properties like G protein-
coupled receptors ligand score, ion channel modulator, kinase 
inhibitor, nuclear receptor ligand, protease inhibitor and enzyme 
inhibitor. The prediction of biological activity of the proposed ligand 
was done by means of PASS (Prediction of Activity Spectra for 
Substances). The 2D structure of the proposed ligands was 
converted into Protein Data Bank (PDB) format using the 
OPENBABEL programme [14-16]. 
For Molecular Docking the 3D structures were taken from PDB 
(Protein Data Bank). The docking of proposed ligands and targets 
was carried out by Discovery Studio. The binding energy of ligands 
was evaluated in terms of negative CDocker energy [17]. 
Insilico molecular modeling  
The 3D structure of the proposed ligands was drawn by ACD Lab 
Chemsketch. Lipinski rule of five reveals the physicochemical 
properties and the drug-likeness properties of the ligands which 
were determined using Mol inspiration software. Lipinski rule 
discusses the molecular weight, number of hydrogen bond donors, 
number of hydrogen bond acceptors, log p-value and number of 
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violations. Molinsipration software exposed the G-Protein Coupled 
Receptors (GPCR) ligand, Ion channel modulator, a kinase inhibitor, 
nuclear receptor ligand, protease inhibitor, and enzyme inhibitor 
property of ligands. PASS software discloses the probability of the 
compound to be active (Pa) or the probability of the compound to be 
inactive (Pi).  
Molecular docking  
Docking and its visualization and analysis of affinity between the targets 
and ligands were analyzed by using the software BIOVIA-Discovery 
Studio and Discovery Studio Visualizer. Initially, the 3D structure of 
targets of interest was selected from the Protein Data Bank (PDB). The 
Protein Data Bank (PDB) ID of α-glucosidase is 3L4T [18], Peroximase 
proliferator-activated receptor gamma (PPARγ)[19] is 4HEE, 
Dipeptidyl–peptidase 4(DPP4) is 4CDC and Insulin like growth factor-1 
(IGF-1) is 3NW5 Structure of targets and ligands were converted from 
MOL format to PDB format by using Open Babel program. The selected 
targets were prepared for docking by adding hydrogen atoms and water 
molecules and minimizing their energy. The ligands were also prepared 
by the removal of unwanted molecules and generating low energy ring 
confirmations. Several poses were generated for targets and ligands. The 
first pose provides the least energy and more stabilized. So the first pose 
was considered as top pose and the top poses of ligand and protein were 
docked. In docking, the active site of native ligand was selected and a 
minimized target was docked against minimized ligand and the 3D 
images of docked structures were visualized [20]. The affinity of the 
ligands with targets of interest was analyzed in terms of energy through 
docking using negative CDocker energy using Discovery Studio.  
The selected hit molecules were further evaluated for favorable 
ADMET (Absorption, Distribution, Metabolism, Excretion, and 
Toxicity) characteristics by Discovery Studio software. In this, 
various parameters such as aqueous solubility, blood-brain 
barrier penetration, absorption level, and ALogP scores were 
analyzed [21].  
RESULTS  
Pharmacophore modeling 
The structure of proposed derivatives drawn by ACD Chemsketch 
was shown in table 1. 
 
Table 1: Structure of proposed derivatives 
































































































The Lipinski rule analysis and drug-likeness properties such as 
G-protein Coupled Receptors Ligand score, Ion channel 
modulator, Kinase inhibitor, nuclear receptor-ligand protease 
inhibitor, and Enzyme inhibitor scores were analyzed by 
Molinspiration ChemInformatic software is shown in (table 2 
and 3). 
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Table 2: Lipinski’s rule analysis of selected proposed 2-aminobenzimidazole derivatives and standard drugs 
Compounds M. W. n. HDO n. HDA Log P n. violation 
B1 248.24 4 7 -0.94 0 
B2 323.36 4 7 2.13 0 
B3 310.31 4 7 2.69 0 
B4 326.31 5 8 2.69 0 
B5 281.32 4 6 2.54 0 
B6 267.29 3 6 1.88 0 
B7 295.30 3 7 0.88 0 
B8 310.32 4 8 0.58 0 
B9 273.34 4 6 0.91 0 
B10 268.8 3 7 0.98 0 
Octreotide 10194 13 14 1.67 3 
Acarbose 645.61 19 14 -5.51 3 
Sitagliptin 407.32 2 6 2.06 0 
Pioglitazone 356.45 1 5 3.07 0 
M. W. Molecular weight; n. HDO: number of hydrogen bond donor; n. HAD: Number of hydrogen acceptor 
 












B1 0.12  0.06 -0.20 –0.66 0.01 0.09 
B2 0.19 0.01 0.18 -0.55 0.10 -0.03 
B3 0.07 -0.05 0.14 -0.44 -0.06 0.02 
B4 0.09 -0.04 0.19 -0.40 -0.05 0.05 
B5 -0.08 -0.13 0.13 -1.04 -0.24 -0.10 
B6 0.14 0.03 0.36 -0.83 -0.10 0.08 
B7 0.18 0.05 0.28 -0.71 -0.01 0.02 
B8 0.03 -0.26 0.23 -0.84 -0.16 -0.09 
B9 0.36 0.18 0.25 -0.77 0.18 0.05 
B10 0.32 0.11 0.62 -0.87 -0.09 0.25 
Octreotide 0.26 0.18 0.25 –0.77 0.18 0.05 
Acarbose –0.02 –0.49 –0.33 –0.29 0.21 0.21 
Sitaglyptin 0.25 –0.27 0.01 –0.60 0.56 –0.06 
Pioglitazone 0.25 –0.51 –0.71 0. 64 –0.09 0.05 
GPCR: G protein-coupled receptor  
 
The PASS software was utilized for the prediction of biological 
activities of proposed compounds. The prediction results is 
presented as the list of activities with suitable ‘Pa’ (Probability to be 
active) and ‘Pi’ (Probability to be inactive) listed in the descending 
order of difference (Pa-Pi)>0. The PASS value of proposed ligands 
was shown in table 4. 
 
Table 4: PASS scores of selected proposed 2-aminobenzimidazole derivatives 
Compound Pa Pi Pa–Pi 
B1 0.257 0.009 0.248 
B2 0.756 0.101 0.655 
B3 0.382 0.024 0.358 
B4 0.725 0.046 0.679 
B5 0.711 0.085 0.626 
B6 0.282 0.014 0.268 
B7 0.759 0.054 0.705 
B8 0.537 0.011 0.526 
B9 0.737 0.061 0.676 
B10 0.728 0.07 0.658 
 
Table 5: Docking scores of selected derivatives and standard drugs on different targets 
Standard drugs and proposed derivatives -CDocker energy  
3L4T 4CDC 4HEE 3NW5 
Acarbose 15.2445 ---- ----  
Sitaglyptin ---- –25.1509 ----  
Pioglitazone ---- ---- –23.7593  
Octreotide ---- ----- ----- -103.883 
B1 -27.2196 -25.7454 -31.7266 -35.9925 
B2 -12.1995 -24.0557 -24.0677 -24.5701 
B3 -29.7231 -28.0454 -43.0464 -25.4024 
B4 -10.0413 -22.1519 -25.1519 -25.5226 
B5 -13.992 -25.4054 -29.4054 -18.3941 
B6 -28.5652 -27.7986 -42.4344 -20.4805 
B7 -12.0385 -17.4860 -27.6506 -20.4699 
B8 -10.2408 -24.6506 -30.1043 -18.2205 
B9 -9.93638 -19.0578 -20.4891 -15.9841 
B10 -18.087 -23.7826 -13.1826 -21.1303 
-CDocker energy: Protein-Ligand interaction energy; 3L4T: α-glucosidase; 4CDC: DPP4 (Dipeptidyl peptidase4); 4HEE: PPARγ (Peroxisome 
proliferator activated gamma receptor); 3NW5: Insulin like growth factor-1. 
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Molecular docking by discovery studio 
Docking evaluation of proposed 2-aminobenzimidazole derivatives 
against the targets of α-glucosidase, Dipeptidyl peptidase 4 and 
Peroxisome proliferator activated receptor and Insulin like growth 
factor-1 inhibitor was done. Acarbose–a well-known α-glucosidase 
inhibitor, sitaglyptin–an established Dipeptidyl peptidase4 inhibitor 
and the pioglitazone–a selective agonist of Peroxisome proliferator 
activated receptor and Octreotide-an insulin like growth factor-1 
inhibitor were used as the standard drugs for comparative evaluation. 
The activities such as binding energy, hydrogen bonding interactions 
of proposed derivatives against all these three receptors were 
analyzed. Docking scores and images of selected standard compounds 
and proposed compounds were presented in table 5 and fig. 1. 
 
 
Docked complex of Acarbose with 3L4T 
 
Docked complex of ligands with 3L4T 
 
Docked complex of Sitaglyptin with 4CDC  Docked complex of ligands with 4CDC 
 
Docked complex of Piogliazone with 4HEE  Docked complex of ligands with 4HEE 
 
Docked complex of Octreotide with 3NW5 
 
Docked complex of ligands with 3NW5 
Fig. 1: Docking of standard drugs and derivatives with targets 
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The active binding site of proposed derivatives and standard drugs on different receptors were presented in table 6.  
 
Table 6: Active binding sites of active of proposed derivatives 
Standard drugs and 
proposed derivatives 
-CDocker energy 
3L4T 4CDC 4HEE 
Acarbose Ser74,Arg29,Cys15   
Sitaglyptin  Asp1,Glu275,Cys234  
Pioglitazone   Leu330,Cys285,Arg288 
B1 Pro158,Ser74,Arg29 Asp1,Gly275,Cys234 Leu330,Cys285,Ala292 
B2 Pro137,Ser74,Arg29 Asp1,Gly276,Cys234 Met364,Leu330,Cys285, 
B3 Ser74,Arg29 Pro158 Pro274,Asp1,Cys234 Leu330,Cys285,Met329 
B4 Ser74,Arg29,Leu160 Asp1,Cys234,Phe278 Lys367,Leu330,Cys285, 
B5 Pro137,Ser74,Arg29 Asp1,Glu275,Cys234 Ala292,Cys285,Arg288 
B6 Ser47,Arg29,Pro158 Pro279, Asp1Cys234 Lys367,Cys285,Arg288 
B7 Val177,Ser74,Arg29 Asp1,Glu273,Cys234 Val333,Cys285,Arg288 
B8 Leu160,Ser74,Arg29 Asp1,Glu275,Gly232 Arg288,Met348,Cys285,  
B9 Pro158,Ser74,Arg29 Ala349,Asp1,Cys234 Leu330,Cys285,Ala292 
B10 Lys48,Ser74,Arg29 Phe278,Asp1,Cys234 Leu330,Cys285, Met329 
The results of analysis of ADMET properties of the proposed derivatives with the help of Discovery studio software is presented in table 7. 
 
Table 7: ADMET analysis of proposed 2-aminobenzimidazole derivatives 
Reference scores 
Parameters 0 1 2 3 4 
Aqueous solubility Nil Very Low Low Good Optimal 
B. B. B penetration Very high High Medium Low Very low 
Absorption level Optimal Good Medium Low Very low 
A log P ≤ 4 
Scores obtained 
Compounds AS BBB P AL Alog P  
B1 4 3 0 -0.041 
B2 3 3 0 1.646 
B3 4 3 0 1.962 
B4 3 4 1 1.72 
B5 3 3 0 2.393 
B6 4 3 0 1.62 
B7 3 3 0  0.581 
B8 3 3 0 1.81 
B9 2 3 0 2.75 
B10 3 3 0 1.092 
AS: Aqueous solubility; BBBP: Blood brain barrier penetration; AL: Absorption level 
 
DISCUSSION  
The analysis of Lipinskirule of five pointed that all the proposed 
derivatives obeyed the Lipinski rule which states that the molecular 
weight of the compound shoulde below 500, the number of 
Hydrogen bond donor should be below 5,the number of Hydrogen 
bond acceptor should below 10 and the log P value should below 5. 
It was found that all the proposed derivatives obey Lipinski rule of 
five or showed no number of violations and therefore they were 
considered as a drug and selected for further analysis [22]. 
Molinspiration Cheminformatics data exposed the drug-likeness 
properties of derivatives. It was observed that all the proposed 
derivatives showed significant bioactive scores on different 
receptors and they were act as a drug [23]. 
The prediction results of PASS are presented as the list of activities 
with suitable ‘Pa’ (Probability to be active) and ‘Pi’ (Probability to be 
inactive). If Pa>0.7, the compound studied is very likely to produce 
this activity in experiments and the chance of being the derivative of 
the known therapeutic agents for this compound is also high. If 
0.5<Pa<0.7, the compound studied is likely to exhibit its activity in 
experiments, but the probability is less and the compound is not so 
similar to the known therapeutic agents. If Pa<0.5, the compound 
studied is unlikely to show its activity in experiments, but if the 
activity is confirmed in the studied compound, it might be a new 
chemical substance. Among 10 proposed derivatives four showed 
the PASS value below 0.7 and the PASS result pointed all the 10 
proposed derivatives showed the value within the range and which 
is expected to be active [24].  
The binding activity of derivatives on the receptor was determined by 
docking with the help of the software, Discovery studio and the affinity 
of the ligands with the targets were analysed in terms of energy 
through docking using-CDocker energy. On the basis of docking among 
the ten derivatives of 2-aminobenzimidazole derivatives B3, B6, B1, 
B8, and B5 showed less energy as compared to their standard drugs on 
3L4T, 4CDC and 4HEE in the ascending order. The-CDocker energy of 
proposed derivatives B3, B6, B1, B8, and B5 produced less energy than 
that of standard drug Acarbose on 3L4T (α-glucosidase). The proposed 
derivatives B3, B6, B1, B8, and, B5 exhibit low binding energy than the 
standard Dipeptidyl–peptidase 4(DDP4) inhibitor drug Sitagliptin on 
4CDC(DPP4 enzyme) [25]. The proposed derivatives B3, B6, B1, B8, and 
B5 exhibit low binding energy than the standard Dipeptidyl–peptidase 
4(PPARγ) agonists drug Pioglitazone on 4HEE(PPARγ receptor) [26]. It 
discloses that these derivatives are more stable in docked receptors. 
Hence can bind their concerned receptors and thereby increasing their 
activity to decrease the blood glucose level. In the case of the 3NW5 
receptor, all the derivatives were docked to the receptors but they 
showed less CDocker energy than that of the standard drug Octreotide 
and this led to the point that the proposed derivatives are less stable in 
3NW5 and they are failed to do their work.  
The derivatives commonly bind with Arg29 and Ser 75 considered 
as active binding sites on 3L4T which are similar to the standard one 
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Acarbose. Acarbose also shows the same binding siteon 3L4T. It 
pointed that the derivatives having an ability to bind with α-
glucosidase receptor. The derivatives commonly bind with Asp1 and 
Glu 275 considered as active binding sites on 4CDC which are similar 
to the standard one Sitagliptin also having the same binding site to 
4CDC and it pointed that the derivatives also can bind with DPP4 
receptor. The derivatives commonly bind with Cys285 and Arg288 
considered as active binding sites on 4HEE which are similar to the 
standard one Pioglitazone which also bind with the same binding 
site on 4HEE and showed their binding affinity towards PPARγ 
receptor. 
The selected hit molecules were further evaluated for favorable 
ADMET (Absorption, Distribution, Metabolism, Excretion, and 
Toxicity) studies. The analysis of ADMET properties of proposed 
derivatives disclosed that the proposed derivatives B1, B3, B5, B6, 
and B8 showed significant aqueous solubility, BBB penetration, 
absorption level, and Alog P value which pointed that they may be 
considered as a good drug [27]. On the basis of Insilico design among 
the ten proposed derivatives four derivatives showed good binding 
ability towards the receptors which were concerned for antidiabetic 
activity. 
CONCLUSION  
Based on molecular modelling among the ten Benzimidazole 
derivatives, five showed good binding scores with α-glucosidase, 
Dipeptidyl–peptidase 4(DPP 4), PPARγ receptors and did not give a 
good score on IGF–I factor. Among the ten derivatives the most five 
acidic compounds binds the α-glucosidase receptor. The more 
aromatic derivatives showed more Dipeptidyl–peptidase 4(DPP4) 
inhibitor activity. The derivatives can change the conformation into 
horseshoe shape and it is a good for binding with Peroximase 
proliferator-activated receptor gamma (PPARγ) receptor. All the 
proposed 2-aminobenzimidazole derivatives are not suitable for 
binding with Insulin like growth factor-1. All the results pointed that 
among the ten 2-aminobenzimidazole derivatives B1, B3, B5, B6, and 
B8 showed better binding affinity towards the α-glucosidase, DPP4 
and PPARγ receptors and hence they may nominate as a good lead in 
antidiabetic category. 
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